|
![]() |
|
|
Nitrofurantoin
drug data and news
Nitrofurantoin drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Nitrofurantoin | ||
| Brand Names/Synonyms | Alfuran; Apo-Nitrofurantoin; Benkfuran; Berkfurin; Ceduran; Chemiofuran; Cistofuran; Cyantin; Cystit; Dantafur; Fua Med; Fuamed; Fur-Ren; Furabid; Furachel; Furadantin; Furadantin Retard; Furadantina Mc; Furadantine; Furadantine Mc; Furadantine-Mc; Furadantoin; Furadoin; Furadoine; Furadonin; Furadonine; Furadontin; Furalan; Furaloid; Furan; Furanite; Furantoin; Furantoina; Furatoin; Furedan; Furina; Furobactina; Furophen T; Furophen T-Caps; Gerofuran; It-Uran; Ituran; Ivadantin; Macpac; Macrobid; Macrodantin; Macrodantina; Macrofuran; Macrofurin; N-Toin; NSC-2107; Nierofu; Nifurantin; Nitoin; Nitrex; Nitrofan; Nitrofur-C; Nitrofuradantin; Nitrofurantoin; Novo-Furantoin; Novofuran; Orafuran; Parfuran; Phenurin; Ro-Antoin; Siraliden; Trantoin; Uerineks; Upiol; Urantoin; Urizept; Uro-Selz; Uro-Tablinen; Urodin; Urofuran; Urofurin; Urolisa; Urolong; Usaf Ea-2; Uvaleral; Welfurin; Zoofurin | ||
| Indication | For the treatment of infection (urinary tract) | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Nitrofurantoin, a nitrofuran antibacterial agent, is available in microcrystalline and macrocrystalline form to treat urinary tract infections caused by many gram-negative and some gram-positive bacteria. | ||
| Mechanism Of Action | Nitrofurantoin inhibits bacterial acetyl-coenzyme A, interfering with the organism's carbohydrate metabolism. The drug also can disrupt bacterial cell wall formation. | ||
| Nitrofurantoin News (When available) |
Rethinking UTI Prophylaxis Mar 1, 2006 A Review of Pregnancy Outcomes After Exposure to Orally Inhaled or ... Aug 12, 2005 Isopak announces spiral jet mill results Aug 1, 2005 Essential drug not available in Mumbai Jul 15, 2005 New Oncology Strategy: Molecular Targeting of Cancer Cells Jun 29, 2005 Pillbox: Nitrofurantoin Apr 17, 2005 Ranbaxy receives FDA approval to market Nitrofurantoin Mar 31, 2005 Eon Labs Receives Final Approval for Nitrofurantoin Monohydrate ... Apr 7, 2005 US nod for Ranbaxy's antibiotic Apr 1, 2005 Ranbaxy gets FDA nod to make capsules Mar 31, 2005 Ranbaxy Receives FDA Approval To Market A Generic Alternative To ... Apr 2, 2005 Macrobid...Ranbaxy wins FDA nod to market its generic alternative Mar 31, 2005 Ranbaxy gets USFDA nod for Macrobid®'s alternate Mar 31, 2005 Ranbaxy gets USFDA nod for new drug Apr 1, 2005 US approves new drug by Ranbaxy Apr 3, 2005 US nod for Ranbaxy's antibiotic Apr 18, 2005 FDA approves Ranbaxy generic drug Apr 1, 2005 Taking liver-taxing drugs calls for periodic testing Apr 5, 2005 Three-Day Antibiotic Regimens for Treating Bladder Infection in ... Feb 22, 2005 Antibiotics for UTIs Feb 22, 2005 | ||
| Dosage Forms | TABLET | ||
| Drug_Category | Anti-Infectives; Anti-Infectives; ATC:J01XE01 | ||
| Absorption | Not Available | ||
| Interactions |
-->Interactions for Nitrofurantoin: Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption. The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate. Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin. The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial. Drug/Laboratory Test Interactions As a result of the presence of nitrofurantoin, a false-positive reaction for glucose in the urine may occur. This has been observed with Benedictís and Fehlingís solutions but not with the glucose enzymatic test. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Not Available | ||
| Chemical IUPAC Name | 1-[(5-nitro-2-furyl)methylideneamino]imidazolidine-2,4-dione | ||
| Chemical Formula | C8H6N4O5 | ||
| Molecular Weight | 238.157 g/mol | ||
| Smiles String | C1C(=O)NC(=O)N1N=CC2=CC=C(O2)[N+](=O)[O-] | ||
| Melting Point | 263 °C | ||
| Water Solubility | 79.5 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | -0.04 | ||
| Isoelectric Point | 7.2 | ||
| Biotransformation | Not Available | ||
| Half Life | 0.3-1 hour. | ||
| Protein Binding [%] | 60% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Nitrofurantoin.html http://www.rxlist.com/cgi/generic/nitro25m.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00191 | ||
| CAS Registry Number | 67-20-9 | ||
| KEGG Compound ID | C07268 | ||
| PubChem ID | SID:149113 | ||
| PharmGKB ID | PA450640 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 319511 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |